A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia
about
Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugsRegulatory mechanism of endothelin receptor B in the cerebral arteries after focal cerebral ischemiaSystematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application.Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer.Identification of a novel cell type-specific intronic enhancer of macrophage migration inhibitory factor (MIF) and its regulation by mithramycin.Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression.Predicting the Drug Safety for Traditional Chinese Medicine through a Comparative Analysis of Withdrawn Drugs Using Pharmacological Network.Emerging role of SETDB1 as a therapeutic target.Sp1 and Sp3 are involved in the full transcriptional activity of centromere protein H in human nasopharyngeal carcinoma cells.IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription.Premithramycinone G, an early shunt product of the mithramycin biosynthetic pathway accumulated upon inactivation of oxygenase MtmOIIMusashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation.Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1.
P2860
Q28533669-1E1ADCA6-F7DA-45BD-BF2D-CE1FDCF1E3D0Q28542526-044980D8-3695-4080-A1FA-E36FD3A56EC8Q34031153-87A0E10D-5E3F-4E00-811D-7A83B95A4946Q34302162-192745F1-1BD5-4113-89CC-53F8947C53F1Q34561618-F65D4A41-C844-4896-9D55-DC4E40F928A1Q34595260-700BF519-0E65-49CE-9EEB-3D960237A9B4Q35098062-ED43815A-35F5-4967-ACB9-5B9551A48169Q36853573-26551B76-570B-4ACB-9960-E02DE99C9B9DQ39079803-61A3D52C-6F02-40F5-9734-92CBB612FFFCQ39334615-A1737DC6-BF34-4724-880A-F6DC9F3C70A8Q39718565-60CFF13E-57BF-4C8E-84E0-86274E6408ECQ42113467-F4D5D04E-1F4F-46DD-8FF0-33C270D43AC2Q46941249-75C029C4-4022-442D-8325-1726E3FD9FC6Q49269166-F36D7EF8-2C47-4391-914B-4D5C8E9B119A
P2860
A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
A pilot study of alpha-interfe ...... se of chronic myeloid leukemia
@ast
A pilot study of alpha-interfe ...... se of chronic myeloid leukemia
@en
A pilot study of alpha-interfe ...... se of chronic myeloid leukemia
@nl
type
label
A pilot study of alpha-interfe ...... se of chronic myeloid leukemia
@ast
A pilot study of alpha-interfe ...... se of chronic myeloid leukemia
@en
A pilot study of alpha-interfe ...... se of chronic myeloid leukemia
@nl
prefLabel
A pilot study of alpha-interfe ...... se of chronic myeloid leukemia
@ast
A pilot study of alpha-interfe ...... se of chronic myeloid leukemia
@en
A pilot study of alpha-interfe ...... se of chronic myeloid leukemia
@nl
P2093
P1433
P1476
A pilot study of alpha-interfe ...... se of chronic myeloid leukemia
@en
P2093
J P Dutcher
P H Wiernik
P304
P356
10.1016/S0145-2126(96)00108-7
P407
P577
1997-05-01T00:00:00Z